View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry

Blog

FDA Accepts Investigational New Drug Application for a Cancer Vaccine Developed by Neon Therapeutics


  • July 28, 2016

  • We are pleased to hear Neon Therapeutics, founded by Immuno-Oncology 360° keynote and MD Anderson Immunology Chair, Dr James Allison, has received the FDA’s acceptance of their IND application for their lead cancer vaccine program NEO-PV-01.

    Dr. James P. Allison in his laboratory

    Dr James Allison, MD Anderson Immunology Chair and IO360° 2017 Keynote Speaker

     

    Neon Therapeutics recently shared data this month at IO360°’s Rational Combinations conference in New York on how they are developing further treatment modalities including next-generation vaccines and T-cell therapies targeting both personalized as well as shared neoantigens. The FDA’s acceptance of the IND enables Neon Therapeutics to initiate their first clinical trial investigating the combination of a NEO-PV-01 with BMS’ Nivolumab in advanced melanoma, NSCLC and bladder cancer. The trial is expected to begin this year.

    Dr James Allison will be delivering a keynote address on Immune Checkpoint Blockade in Cancer Therapies: New Insights and Opportunities for Cures at the 3rd Annual Immuno-Oncology 360° program taking place January 31- February 3rd, 2017 in NYC.

    To read the full press release: http://www.businesswire.com/news/home/20160729005446/en/Neon-Therapeutics-Announces-FDA-Acceptance-Investigational-Drug

    To learn more about the 3rd Annual Immuno-Oncology 360° conference visit: http://theconferenceforum.org/conferences/immuno-oncology-360/overview/